» Articles » PMID: 22007699

How Psoriasis Patients Perceive, Obtain, and Use Biologic Agents: Survey from an Academic Medical Center

Overview
Publisher Informa Healthcare
Specialty Dermatology
Date 2011 Oct 20
PMID 22007699
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The availability of new biologic agents for the treatment of psoriasis provides hope for improved quality of life outcomes. However, the way patients come to use biologics, the potential barriers they encounter, and their attitudes towards using these medications are still not well studied. Here, we conducted a survey of 106 psoriasis patients at an academic medical center to discern patient attitudes towards biologics. We found that most patients learn of biologics through their physician and perform follow-up research using the Internet. Most patients did not find it difficult to make the decision to start a biologic. Difficulty in obtaining biologics was associated with age less than 55 (p = 0.01), lower income level (p = 0.007), and lack of insurance (p = 0.04). Patients were found to have high satisfaction and compliance rates on biologics. Of patients who missed a dose of their biologic, this was mainly due to logistical reasons such as not having the medication or forgetting to take it, rather than being depressed or overwhelmed. Patients with lower income levels had increased cut backs in personal expenses due to co-payments (p = 0.001). Among respondents, the mean annual out-of-pocket expense for a biologic was $557.12 per year, with a range of $0-7000.

Citing Articles

Efficacy and Safety of Orally Administered East Asian Herbal Medicine Combined with Narrowband Ultraviolet B against Psoriasis: A Bayesian Network Meta-Analysis and Network Analysis.

Jo H, Kim H, Baek E, Seo J, Lee D Nutrients. 2024; 16(16).

PMID: 39203826 PMC: 11357435. DOI: 10.3390/nu16162690.


Management of Guttate Psoriasis: A Systematic Review.

Zhou T, Koussiouris J, Kim L, Vender R J Cutan Med Surg. 2024; 28(6):577-584.

PMID: 39080843 PMC: 11619194. DOI: 10.1177/12034754241266187.


Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program.

Jung H, Kim S, Cho S, Jo S Sci Rep. 2024; 14(1):4139.

PMID: 38374130 PMC: 10876659. DOI: 10.1038/s41598-024-54447-5.


Unmet needs in the management of psoriasis in Latin America: a systematic review.

Ossanai Schoenardie B, Oliveira Almeida R, Hanemann T, Ossanai Schoenardie A, Lucas Ribeiro A, Boza J An Bras Dermatol. 2023; 99(2):244-258.

PMID: 38061962 PMC: 10943312. DOI: 10.1016/j.abd.2023.04.006.


Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong.

Li Y, Lau L, Peng K, Zhang D, Dong D, Wong I BMJ Open. 2023; 13(10):e069681.

PMID: 37827733 PMC: 10583073. DOI: 10.1136/bmjopen-2022-069681.


References
1.
Sizto S, Bansback N, Feldman S, Willian M, Anis A . Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009; 160(6):1264-72. DOI: 10.1111/j.1365-2133.2008.08962.x. View

2.
Katugampola R, Lewis V, Finlay A . The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007; 156(5):945-50. DOI: 10.1111/j.1365-2133.2007.07817.x. View

3.
Gottlieb A, Korman N, Gordon K, Feldman S, Lebwohl M, Koo J . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008; 58(5):851-64. DOI: 10.1016/j.jaad.2008.02.040. View

4.
Castelo-Soccio L, Van Voorhees A . Long-term efficacy of biologics in dermatology. Dermatol Ther. 2009; 22(1):22-33. PMC: 2880851. DOI: 10.1111/j.1529-8019.2008.01213.x. View

5.
Stein K, Pearce D, Feldman S . The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005; 24(1):52-7. DOI: 10.1016/j.sder.2005.01.004. View